{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05101551",
            "orgStudyIdInfo": {
                "id": "IRB-66573"
            },
            "secondaryIdInfos": [
                {
                    "id": "PEDSHEMAML0008",
                    "type": "OTHER",
                    "domain": "OnCore"
                },
                {
                    "id": "POE22-01",
                    "type": "OTHER",
                    "domain": "POETIC study number"
                },
                {
                    "id": "Pro00060706",
                    "type": "OTHER",
                    "domain": "Advarra IRB number"
                }
            ],
            "organization": {
                "fullName": "Stanford University",
                "class": "OTHER"
            },
            "briefTitle": "Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy",
            "officialTitle": "A Phase I Protocol for Relapsed Pediatric AML to Determine the Safety and Efficacy of the PARP Inhibitor Talazoparib in Combination With Chemotherapy",
            "acronym": "PARPAML",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "study-of-talazoparib-in-combination-with-chemotherapy-in-relapsed-pediatric-aml-to-determine-safety-and-efficacy"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-02-23",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-03",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-03",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-10-28",
            "studyFirstSubmitQcDate": "2021-10-28",
            "studyFirstPostDateStruct": {
                "date": "2021-11-01",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-23",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-28",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Jennifer Lauren Kamens",
                "investigatorTitle": "Instructor Pediatrics - Hematology/Oncology",
                "investigatorAffiliation": "Stanford University"
            },
            "leadSponsor": {
                "name": "Jennifer Lauren Kamens",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Gateway for Cancer Research",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a Phase 1, open label, multicenter, dose finding study with dose expansion intended to evaluate the safety and tolerability of talazoparib in combination with conventional chemotherapy. Preliminary estimates of efficacy will be obtain through a dose expansion cohort receiving the maximum tolerated dose from the dose escalation phase of the study.\n\nThis study aims to determine the safety of talazoparib in combination with conventional chemotherapy and to establish the maximum tolerated dose of all 3 drugs when given in combination. A preliminary estimate of efficacy through a dose expansion phase is a secondary aim."
        },
        "conditionsModule": {
            "conditions": [
                "Acute Myeloid Leukemia"
            ],
            "keywords": [
                "PARP Inhibitor"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 34,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Talazoparib with topotecan and gemcitabine",
                    "type": "EXPERIMENTAL",
                    "description": "Talazoparib will be administered orally on Days 1 to 5 concurrently with topotecan and a single dose of gemcitabine on Day 1 of 28 day cycle for 1 or 2 cycles. Subjects on dose level 5 will receive an additional 5 day treatment course of talazoparib on days 15-19.",
                    "interventionNames": [
                        "Drug: Talazoparib",
                        "Drug: Topotecan",
                        "Drug: Gemcitabine"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Talazoparib",
                    "description": "Talazoparib will be administered in escalating doses based on current dose level.\n\n* Dose Level 1: 400 \u00b5g/m2/dose once daily\n* Dose Level 2: 600 \u00b5g/m2/dose BID on Day 1, then daily on Days 2 to 5\n* Dose Level 3: 600 \u00b5g/m2/dose BID on Day 1, then daily on Days 2 to 5\n* Dose Level 4: 600 \u00b5g/m2/dose BID on Day 1, then daily on Days 2 to 5\n* Dose Level 5: 600 ug/m2/dose BID on Day 1, then daily on Days 2 to 5 and 15 to19",
                    "armGroupLabels": [
                        "Talazoparib with topotecan and gemcitabine"
                    ],
                    "otherNames": [
                        "Talzenna"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Topotecan",
                    "description": "Administered IV route on Days 1 to 5\n\n* Dose Level -2: 1 mg/m2/dose once daily by IV days 1 to 5\n* Dose Level -1: 2 mg/m2/dose once daily by IV days 1 to 5\n* Dose Level 1: 2 mg/m2/dose once daily by IV days 1 to 5\n* Dose Level 2: 2 mg/m2/dose once daily by IV days 1 to 5\n* Dose Level 3: 3 mg/m2/dose once daily by IV days 1 to 5\n* Dose Level 4: 4 mg/m2/dose once daily by IV days 1 to 5\n* Dose Level 5: 4 mg/m2/dose once daily by IV days 1 to 5",
                    "armGroupLabels": [
                        "Talazoparib with topotecan and gemcitabine"
                    ],
                    "otherNames": [
                        "Hycamtin"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Gemcitabine",
                    "description": "Single dose (IV) of gemcitabine on Day 1 of each 28 day cycle for 1 cycle.\n\n* Dose Level -2: 600 mg/m2/dose once daily by IV days 1\n* Dose Level -1: 600 mg/m2/dose once daily by IV days 1\n* Dose Level 1: 1200 mg/m2/dose once daily by IV days 1\n* Dose Level 2: 1200 mg/m2/dose once daily by IV days 1\n* Dose Level 3: 1200 mg/m2/dose once daily by IV days 1\n* Dose Level 4: 1200 mg/m2/dose once daily by IV days 1\n* Dose Level 5: 1200 mg/m2/dose once daily by IV days 1",
                    "armGroupLabels": [
                        "Talazoparib with topotecan and gemcitabine"
                    ],
                    "otherNames": [
                        "Gemzar",
                        "Infugem"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Dose limiting toxicity (DLT).",
                    "description": "Patient safety is assessed as dose limiting toxicity (DLT). The outcome is the number of DLT events. A DLT event is defined as:\n\n* Hematologic DLT - Failure to recover peripheral ANC to \\> 500/\u00b5L or non-transfusion-dependent platelets to \\> 25,000/\u00b5L by Day 42 from the start of Cycle 1 of chemotherapy will be considered a DLT, unless the delay in count recovery is due to another identifiable factor\n* Non-Hematologic DLT-Any \u2265 Grade 4 non-hematological organ toxicity, including Hy's Law case is a DLT with the following exceptions:\n* Grade 4 infection or fever \u2264 7 days in duration.\n* Grade 4 electrolyte or laboratory abnormalities correctable with supportive therapy or that resolve to \\< Grade 3 within 72 hours.\n* Grade 4 elevation in hepatic transaminases that resolves to \u2264 Grade 2 within 7 days.\n* Grade 4 tumor lysis syndrome must resolve in \u2264 7 days without evidence of end-organ damage.",
                    "timeFrame": "28 days after starting therapy (ie, single course of therapy)."
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Objective Response (OR)",
                    "description": "Objective response includes all participants that achieve complete or partial response, and assessed for all participants treated at the maximum tolerated dose.\n\n* Complete remission: Bone marrow MRD \\< 5% by flow cytometry, One of ANC \\< 500/\u03bcL OR platelets \\< 50,000/\u03bcL,without transfusions,No extramedullary disease\n* Complete remission without hematologic recovery: Bone marrow MRD \\< 5% by flow cytometry, One of ANC \\< 500/\u03bcL OR platelets \\< 50,000/\u03bcL,without transfusions, No extramedullary disease\n* Partial response: Decrease of at least 50% of blasts by MRD and \u2265 5% to 25% blasts by flow cytometry.Enrolled patients with fewer than 5% blasts by MRD are not evaluable.\n* No response: No change in clinical or laboratory status.For patients with \\< 5% of blasts, no response is defined as failure to achieve MRD negative CR or MRD negative CRi.\n* Progressive Disease: Deterioration of initial disease status\n* MRD negative: \\< 0.05% of leukemic blasts by flow cytometry.",
                    "timeFrame": "28 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Aged \u2264 21 years.\n2. Acute myeloid leukemia (AML) OR acute leukemia of ambiguous lineage (acute undifferentiated leukemia or mixed phenotype acute leukemia), specified as either refractory (persistent leukemia after at least 2 courses of induction chemotherapy) or relapsed, and further defined as any one of the criteria below:\n\n   1. Bone marrow specimen \u2265 5% leukemic blasts by flow, as assessed by Hematologics Inc.\n   2. A single bone marrow specimen with at least 2 tests demonstrates \u2265 1% leukemic blasts by flow cytometry (as assessed by Hematologics Inc), AND at least one of the following:\n\n      * Karyotypic abnormality with at least 1 metaphase similar or identical to diagnosis\n      * FISH abnormality identical to one present at diagnosis\n      * PCR or NGS-based demonstration of leukemogenic lesion identical to diagnosis\n   3. Rising MRD \\> 0.1% by flow cytometry on \u2265 2 serial samples, as assessed by Hematologics Inc.\n   4. If an adequate bone marrow sample is not obtained, subjects may be enrolled if there is unequivocal evidence of leukemia based on \u2265 5% blasts in the peripheral blood\n3. \\> 60 days has passed since hematopoietic stem cell transplant.\n4. Patients who have undergone previous allogeneic stem cell transplantation who are otherwise eligible must also be without evidence of any active graft versus host disease (GVHD), and off calcineurin inhibitors for at least 28 days (four weeks) prior to therapy. A physiologic dose of prednisone up to 3 mg/m2 (and a maximum of 7.5 mg) or equivalent other steroid dose is allowable.\n5. A minimum of 14 days has passed since completion of myelosuppressive therapy or gemtuzumab ozogamicin and all nonhematologic toxicities have resolved to Grade 0 or 1.\n6. A minimum of 24 hours has elapsed since the patient has completed any low-dose or non-myelosuppressive therapy (e.g., hydroxyurea or low-dose cytarabine (up to 100 mg/m2).\n7. Lansky (subjects \u2264 16 years old) or Karnofsky (subjects \\> 16 years old) score \u2265 50.\n8. WBC \u2264 50,000/uL. This may be achieved using cytoreductive therapy such as hydroxyurea or low-dose cytarabine (up to 100 mg/m2/dose)\n9. Total bilirubin \u2264 2.0 x institutional upper limit of normal (ULN) for age.\n10. AST/ALT \u2264 5 x ULN for age\n11. Left ventricular ejection fraction \u2265 40% or ECHO shortening fraction \u2265 25%.\n12. Estimated serum creatinine \u2265 60 mL/min/1.73m2\n\nExclusion Criteria:\n\n1. Patients receiving or planning to receive ANY concurrent cancer therapy, including chemotherapy, radiation therapy, immunotherapy or biologic therapy.\n2. Patients with down syndrome.\n3. Patients with Acute Promyelocytic leukemia (APL) or Juvenile Myelomonocytic Leukemia (JMML).\n4. Patients with Bone Marrow Failure Syndrome.\n5. Pregnant subjects or those unwilling to use an effective method of birth control.\n6. Female subjects with infants who do NOT agree to abstain from breastfeeding.\n7. Inability or unwillingness of legal guardian/representative to give written informed consent.\n8. Patients with uncontrolled systemic fungal, bacterial, viral or other infection.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "maximumAge": "21 Years",
            "stdAges": [
                "CHILD",
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Sophia Brodsky",
                    "role": "CONTACT",
                    "phone": "(650)721-4087",
                    "email": "sophia.brodsky@stanford.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Jennifer L Kamens, MD",
                    "affiliation": "Stanford Universiy",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Phoenix Children's Hospital",
                    "status": "RECRUITING",
                    "city": "Phoenix",
                    "state": "Arizona",
                    "zip": "85016",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Chris Oless, MD",
                            "role": "CONTACT",
                            "phone": "602-933-0920",
                            "email": "coless@phoenixchildrens.com"
                        },
                        {
                            "name": "Michael Henry, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.44838,
                        "lon": -112.07404
                    }
                },
                {
                    "facility": "Arkansas Children's Hospital",
                    "status": "RECRUITING",
                    "city": "Little Rock",
                    "state": "Arkansas",
                    "zip": "72202",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Kevin Bielamowicz, MD",
                            "role": "CONTACT",
                            "phone": "501-364-4405",
                            "email": "kjbielamowicz2@uams.edu"
                        },
                        {
                            "name": "Kevin J Bielamowicz, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.74648,
                        "lon": -92.28959
                    }
                },
                {
                    "facility": "City of Hope",
                    "status": "RECRUITING",
                    "city": "Duarte",
                    "state": "California",
                    "zip": "91010",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Lindsey Murphy, MD",
                            "role": "CONTACT",
                            "phone": "626-218-0948",
                            "email": "lmurphy@coh.org"
                        },
                        {
                            "name": "Lindsey Murphy, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.13945,
                        "lon": -117.97729
                    }
                },
                {
                    "facility": "Stanford University",
                    "status": "RECRUITING",
                    "city": "Stanford",
                    "state": "California",
                    "zip": "94305",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sophia Brodsky",
                            "role": "CONTACT",
                            "phone": "650-721-4087",
                            "email": "sophia.brodsky@stanford.edu"
                        },
                        {
                            "name": "Jennifer Kamens",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Tanja Gruber",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Norman Lacayo",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.42411,
                        "lon": -122.16608
                    }
                },
                {
                    "facility": "Pennsylvania State University Hershey Medical Center",
                    "status": "RECRUITING",
                    "city": "Hershey",
                    "state": "Pennsylvania",
                    "zip": "17033-0850",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Valerie Brown, MD, PhD",
                            "role": "CONTACT",
                            "phone": "717-531-6012",
                            "email": "vbrown1@hmc.psu.edu"
                        },
                        {
                            "name": "Valerie Brown, MD, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.28592,
                        "lon": -76.65025
                    }
                },
                {
                    "facility": "St. Jude Children's Research Hospital",
                    "status": "RECRUITING",
                    "city": "Memphis",
                    "state": "Tennessee",
                    "zip": "38105",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Seth Karol, MD",
                            "role": "CONTACT",
                            "phone": "901-595-1617",
                            "email": "seth.karol@STJUDE.org"
                        },
                        {
                            "name": "Seth Karol, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.14953,
                        "lon": -90.04898
                    }
                },
                {
                    "facility": "University of Utah",
                    "status": "RECRUITING",
                    "city": "Salt Lake City",
                    "state": "Utah",
                    "zip": "84108",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Spencer Mangum, MD",
                            "role": "CONTACT",
                            "phone": "801-662-4700",
                            "email": "Spencer.Mangum@hsc.utah.edu"
                        },
                        {
                            "name": "Spencer Mangum, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.76078,
                        "lon": -111.89105
                    }
                },
                {
                    "facility": "University of Wisconsin - American Family Children's Hospital",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Madison",
                    "state": "Wisconsin",
                    "zip": "53792",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Rebecca Richards, MD",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Rebecca Richards, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.07305,
                        "lon": -89.40123
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M10945",
                    "name": "Leukemia",
                    "relevance": "LOW"
                },
                {
                    "id": "M10955",
                    "name": "Leukemia, Myeloid",
                    "relevance": "LOW"
                },
                {
                    "id": "M18127",
                    "name": "Leukemia, Myeloid, Acute",
                    "relevance": "LOW"
                },
                {
                    "id": "T3995",
                    "name": "Myeloid Leukemia",
                    "asFound": "Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T182",
                    "name": "Acute Myeloid Leukemia",
                    "asFound": "Acute Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T188",
                    "name": "Acute Non Lymphoblastic Leukemia",
                    "relevance": "LOW"
                },
                {
                    "id": "T170",
                    "name": "Acute Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000093542",
                    "term": "Gemcitabine"
                },
                {
                    "id": "D000019772",
                    "term": "Topotecan"
                },
                {
                    "id": "C000586365",
                    "term": "Talazoparib"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000964",
                    "term": "Antimetabolites, Antineoplastic"
                },
                {
                    "id": "D000000963",
                    "term": "Antimetabolites"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000059004",
                    "term": "Topoisomerase I Inhibitors"
                },
                {
                    "id": "D000059003",
                    "term": "Topoisomerase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000067856",
                    "term": "Poly(ADP-ribose) Polymerase Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M21674",
                    "name": "Topotecan",
                    "asFound": "Staff",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2985",
                    "name": "Gemcitabine",
                    "asFound": "Mg/kg",
                    "relevance": "HIGH"
                },
                {
                    "id": "M205",
                    "name": "Poly(ADP-ribose) Polymerase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M281046",
                    "name": "Talazoparib",
                    "asFound": "Stereotactic Body Radiation",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4281",
                    "name": "Antimetabolites",
                    "relevance": "LOW"
                },
                {
                    "id": "M29349",
                    "name": "Topoisomerase I Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M29348",
                    "name": "Topoisomerase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}